Purespring Therapeutics
Generated by Meeveem AI
"Precision gene therapy targeting podocytes to preserve kidney function and prevent renal failure"
London
•51 - 250 Employees
•Biotechnology
About Purespring Therapeutics
Purespring develops targeted genetic therapies for glomerular kidney diseases, focusing on patients with IgA nephropathy and rare genetic disorders that lead to renal failure. The company's GlomThera platform delivers gene therapy directly to podocytes, specialised kidney cells implicated in disease progression. This precision approach uses more than 10 times lower doses than systemic therapies, reducing off-target effects. The treatments address a critical gap for over 788 million people affected by kidney disease globally. By treating disease at its source, Purespring aims to transform the trajectory for patients facing dialysis or transplantation, offering a once and done therapy that helps patients live fuller, healthier lives.
58
Team Members
2021
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where kidney disease no longer progresses to dialysis or transplantation, where genetic therapies preserve renal function and patients maintain their quality of life without the burden of end stage renal disease.
Our Mission
At Purespring, our mission is to empower patients with kidney diseases to live fuller, healthier lives through targeted, first in class genetic therapies that preserve renal function.